Study of a new drug for advanced solid tumors after immunotherapy
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor (cancer that has spread).
- You have already received at least 12 weeks of a type of immunotherapy called anti-PD-1 or anti-PD-L1.
- Your cancer got worse while on that immunotherapy or within 12 weeks after stopping it.
- You have at least one tumor that can be measured on a scan.
- You do not have active brain metastases or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Hear when a new Advanced or Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.